###begin article-title 0
###xml 135 143 <span type="species:ncbi:9606">patients</span>
UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 195 196 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 210 213 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">458</sup>
###xml 219 226 219 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7 </italic>
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268</sup>
###xml 239 247 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 251 253 251 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85</sup>
###xml 263 271 263 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 275 278 275 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">213</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) enzymes are involved in removing sex hormones from circulation. Polymorphic variation in five UGT and SULT genes - UGT1A1 ((TA)6/(TA)7), UGT2B4 (Asp458Glu), UGT2B7 (His268Tyr), UGT2B15 (Asp85Tyr), and SULT1A1 (Arg213His) - may be associated with circulating sex hormone concentrations, or the risk of an estrogen receptor-negative (ER-) or progesterone receptor-negative (PR-) tumor.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 216 221 <span type="species:ncbi:9606">women</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
Logistic regression analysis was used to estimate the odds ratios of an ER- or PR- tumor associated with polymorphisms in the genes listed above for 163 breast cancer patients from a population-based cohort study of women in western Washington. Adjusted geometric mean estradiol, estrone, and testosterone concentrations were calculated within each UGT and SULT genotype for a subpopulation of postmenopausal breast cancer patients not on hormone therapy 2-3 years after diagnosis (n = 89).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 70 72 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 79 81 79 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 116 124 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 128 136 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 294 302 294 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 306 314 306 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 455 457 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 496 504 496 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 325 330 <span type="species:ncbi:9606">women</span>
###xml 422 427 <span type="species:ncbi:9606">women</span>
###xml 481 486 <span type="species:ncbi:9606">women</span>
###xml 535 540 <span type="species:ncbi:9606">women</span>
The variant allele of UGT1A1 was associated with reduced risk of an ER- tumor (P for trend = 0.03), and variants of UGT2B15 and SULT1A1 were associated with non-statistically significant risk reductions. There was some indication that plasma estradiol and testosterone concentrations varied by UGT2B15 and SULT1A1 genotypes; women with the UGT2B15 Asp/Tyr and Tyr/Tyr genotypes had higher concentrations of estradiol than women with the Asp/Asp genotype (P = 0.004). Compared with women with the SULT1A1 Arg/Arg and Arg/His genotypes, women with the His/His genotype had elevated concentrations of testosterone (P = 0.003).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Exposure to increased concentrations of both estrogens and androgens has been implicated in the development of breast cancer [1-3]. There are varied mechanisms by which sex hormones might act to propagate malignancy; at the same time, there are only a few pathways by which these hormones are inactivated and removed from circulation. Glucuronidation and sulfonation are two of the pathways through which sex hormones can be metabolized to inactive compounds [4-6].
###end p 10
###begin p 11
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Glucuronidation is catalyzed by UDP-glucuronosyltransferase (UGT) enzymes and involves the covalent addition of glucuronic acid, resulting in more hydrophilic compounds that are excreted from the body via urine or bile [6,7]. UGT1A1, UGT2B4, UGT2B7, and UGT2B15 are among the UGT enzymes that metabolize steroid hormones [4].
###end p 11
###begin p 12
###xml 103 104 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 105 107 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 223 224 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 223 224 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></sub>
###xml 229 231 226 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 280 282 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 283 285 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 319 321 316 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 355 357 352 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8 </sub>
###xml 408 417 405 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 430 432 427 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 450 452 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 453 455 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 680 682 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 683 685 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 581 586 <span type="species:ncbi:9606">women</span>
###xml 673 678 <span type="species:ncbi:9606">women</span>
The UGT1A1 protein glucuronidates estriol, 17beta-estradiol, ethinylestradiol, and catechol estrogens [8-11]. Variation in glucuronidation between individuals is due primarily to a variable number of TA repeats in the A(TA)nTAA (n = 5-8) promoter sequence in the TATA-box region [12,13]. Among the variant alleles, (TA)7 (the most common variant) and (TA)8 are associated with lower transcriptional activity in vitro than the (TA)6 wild-type allele [12-14]. An increasing number of TA repeats has been associated with increased breast cancer risk in premenopausal African-American women, but not postmenopausal African-American or premenopausal or postmenopausal Caucasian women [14,15].
###end p 12
###begin p 13
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 124 127 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">458</sup>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7 </italic>
###xml 675 678 675 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268</sup>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 991 994 991 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink">19 </sub>
###xml 1078 1080 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1081 1083 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1084 1086 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1111 1119 1104 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 1128 1130 1121 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85</sup>
###xml 1136 1138 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1168 1169 1161 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 1169 1173 1162 1166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 1232 1241 1218 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1290 1292 1276 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
The UGT2B4 enzyme glucuronidates catechol estrogens, estriol, and bile acids [16-18]. A polymorphism in the UGT2B4 gene (Asp458Glu) has been reported [16]. The two alleles have similar tissue distributions and currently there is little biochemical evidence to suggest different substrate specificities between the two isoforms [16,19]. However, it has not yet been determined whether this polymorphism affects UGT2B4 protein function through other mechanisms. The UGT2B7 enzyme glucuronidates a wide variety of steroids, including catechol estrogens, estriol, and hydroxylated androgens [10,17,18,20-25]. A polymorphism in the UGT2B7 gene results in an amino acid change (His268Tyr) [22], possibly near the proposed substrate-binding site of the protein [22,26]. The two alleles seem to have similar enzymatic activities for most substrates [10,24,27], with the possible exception of androsterone, estriol, and estradiol [21-23,25]. The UGT2B15 enzyme conjugates catechol estrogens and the C19 sex steroids testosterone, dihydrotestosterone, and androstane-3alpha, 17beta-diol [18,28-30]. A polymorphism in the UGT2B15 gene (Asp85Tyr) [28] results in an allele with a Vmax for androstane-3alpha, 17beta-diol and dihydrotestosterone in vitro that is double that of the aspartic acid allele [28].
###end p 13
###begin p 14
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 399 407 399 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 416 419 416 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">213</sup>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 532 541 532 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 607 615 607 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 701 706 <span type="species:ncbi:9606">women</span>
Sulfotransferases (SULTs) comprise another group of enzymes involved in the removal of circulating bioactive sex hormones. The SULT1A1 enzyme can catalyze the sulfonation of estrogens to form inactive estrogen sulfates [6,31,32]. It has been proposed that estrone sulfate serves as an inactive reservoir in the blood from which estrone and estradiol can be regenerated [6,33]. A polymorphism in the SULT1A1 gene (Arg213His) has been identified [34]. Individuals homozygous for the histidine allele have lower platelet SULT activity in vitro than wild-type and heterozygous individuals [34,35]. Further, the SULT1A1 variant allele is associated with an elevated breast cancer risk among postmenopausal women [36].
###end p 14
###begin p 15
###xml 318 325 318 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 452 459 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 547 554 547 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 655 663 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1089 1095 1089 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 1097 1103 1097 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4</italic>
###xml 1105 1111 1105 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 1113 1120 1113 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 1126 1134 1126 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 1251 1259 <span type="species:ncbi:9606">patients</span>
Because the UGT and SULT enzymes are important in the inactivation and removal of bioactive sex hormones from target tissues, investigating the association between polymorphisms in these genes and circulating sex hormone concentrations might help to elucidate the potential functional relevance of these polymorphisms in vivo. These observations might support experimental results suggesting a functional role for polymorphisms in UGT1A1, UGT2B15, and SULT1A1, or might generate new hypotheses about the potential effect of sequence variations in UGT2B4 and UGT2B7, for which there is relatively little biochemical evidence suggesting a functional effect in vitro. With this purpose we investigated the association between these polymorphisms and circulating sex hormone concentrations in postmenopausal breast cancer patients not taking hormones 2-3 years after diagnosis. In view of increasing evidence that hormones are important in the development of hormone-dependent and hormone-independent breast cancer tumors [37-41], we also examined the association between polymorphisms in the UGT1A1, UGT2B4, UGT2B7, UGT2B15, and SULT1A1 genes and breast tumor estrogen receptor (ER) and progesterone receptor (PR) status in newly diagnosed breast cancer patients.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Study population
###end title 17
###begin p 18
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1394 1395 1394 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1463 1471 1463 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 2507 2509 2507 2509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 126 131 <span type="species:ncbi:9606">women</span>
###xml 300 312 <span type="species:ncbi:9606">Participants</span>
###xml 694 699 <span type="species:ncbi:9606">women</span>
###xml 926 931 <span type="species:ncbi:9606">women</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
###xml 1068 1073 <span type="species:ncbi:9606">women</span>
###xml 1141 1146 <span type="species:ncbi:9606">women</span>
###xml 1212 1217 <span type="species:ncbi:9606">women</span>
###xml 1219 1224 <span type="species:ncbi:9606">Women</span>
###xml 1308 1313 <span type="species:ncbi:9606">women</span>
###xml 1432 1437 <span type="species:ncbi:9606">women</span>
###xml 1505 1516 <span type="species:ncbi:9606">participant</span>
###xml 1769 1774 <span type="species:ncbi:9606">women</span>
###xml 2052 2057 <span type="species:ncbi:9606">women</span>
###xml 2219 2224 <span type="species:ncbi:9606">women</span>
###xml 2335 2340 <span type="species:ncbi:9606">women</span>
The Health, Eating, Activity, and Lifestyle (HEAL) study is a population-based, multicenter prospective cohort study in which women with breast cancer are followed to determine whether breast cancer prognosis is associated with diet, physical activity, sex hormones, weight, or other exposures [42]. Participants in the HEAL study were identified through Surveillance, Epidemiology, and End Results (SEER) registries in western Washington state, in New Mexico, and in Los Angeles County, California. The analyses presented here are limited to breast cancer cases in Washington state who were identified through the western Washington SEER cancer registry between 1996 and 1999. To be eligible, women had to be newly diagnosed with stage 0, I, II, or IIIa breast cancer, living in King, Pierce, or Snohomish counties, and to have clinic measurements and a blood draw within 4 to 12 months of diagnosis. Because the majority of women were either Caucasian or Asian, the analyses were restricted to these two races. Of 202 patients interviewed in western Washington, 184 women were Caucasian or Asian and had a blood draw at baseline. Of these women, the ER and PR status of the breast tumor was determined for 163 women. Women for whom ER and PR status were determined did not significantly differ from the 21 women with unknown receptor status with respect to characteristics presented in Table 1, with the exception that the latter women were more likely to have in situ breast cancer (31% versus 52%). A participant's menopausal status was determined by using self-reported information on estrogen and tamoxifen use, prior ovarian surgery or hysterectomy, menstrual history, and measured values of estrone, estradiol, and follicle-stimulating hormone. At baseline, 61 women were classified as premenopausal, 98 as postmenopausal and 4 were unable to be classified. Data from a follow-up interview and blood draw that occurred 24 months after initial enrollment were used for the analysis of serum hormone concentrations. At the 24-month follow-up, 35 women were classified as premenopausal, 114 as postmenopausal, and 16 were unable to be classified. Because we were unable to collect blood samples from premenopausal women at the same point in the menstrual cycle, hormone analyses were limited to postmenopausal Caucasian and Asian women who had complete data for estrone, estradiol, height and weight, and who were not taking estrogen or progesterone replacement hormones at the time of the blood draw (n = 89). There was no correlation between hormone concentrations and time from breast cancer diagnosis to blood draw at the 24-month follow-up.
###end p 18
###begin p 19
###xml 48 59 <span type="species:ncbi:9606">participant</span>
Written informed consent was obtained from each participant. The protocol was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center.
###end p 19
###begin title 20
Data collection
###end title 20
###begin p 21
###xml 215 223 <span type="species:ncbi:9606">Patients</span>
###xml 773 780 <span type="species:ncbi:4097">tobacco</span>
Data from two time points were used in this study. The first time point was the time of study enrollment, 4-12 months after breast cancer diagnosis. The second time point was about 24 months after study enrollment. Patients were mailed study questionnaires to complete and bring with them to their clinic evaluations at the Fred Hutchinson Cancer Research Center Prevention Studies Clinic. Information was collected on the following: dietary intake; health habits; reproductive and menstrual history; history of use of oral contraceptives and hormone replacement therapy; medical history, including history of endocrine problems and other medical problems; history of benign breast disease; family history of breast cancer, other cancers, and diabetes mellitus; history of tobacco, caffeine, and alcohol use; lifetime weight patterns; detailed current and pre-diagnostic physical activity habits; mammographic screening; and selected demographic data. Standard height and weight measurements were obtained by trained staff during home or clinic visits. Percentage body fat was measured by bioelectric impedance (RJL Multifrequency Bioelectric Impedance Analyzer, Clinton Township, MI). Bioelectrical impedance measurements were made with standard electrode placements after a minimum 4-hour fast.
###end p 21
###begin title 22
Hormone assays
###end title 22
###begin p 23
A 30 ml fasting blood draw was collected at the 24-month follow-up visit to determine circulating concentrations of sex hormones. Blood was processed within 1 hour of collection; serum, plasma, and buffy coat aliquots were stored at -70 to -80degreesC. Dates of sample collection and processing, time of day of blood collection, and time since last meal were recorded.
###end p 23
###begin p 24
Estrone and estradiol assays were performed at Quest Diagnostics Nichols Institute (San Juan Capistrano, CA) between July and August 2001. The testosterone assay was performed in Dr Frank Stanczyk's laboratory at the University of Southern California between April and June 2002. Samples were assigned randomly to assay batches and ordered randomly within each batch. Laboratory personnel performing the assays were blinded to subject identity.
###end p 24
###begin p 25
Estrone and estradiol assay methods consisted of organic solvent extraction, followed by Celite column partition chromatography before quantification by radioimmunoassay. The reported sensitivities of these assays are less than 10 pg/ml and less than 2 pg/ml, respectively. Testosterone was also measured by extraction, Celite column chromatography, and radioimmunoassay; this method has a sensitivity of 1 ng/dl. Twenty replicated samples and eight pooled quality-control samples (two samples per batch) were included in the estrone and estradiol blood assays. For estrone and estradiol, the intra-assay coefficients of variation (CVs) were 13.3% and 28.8%, respectively, and the total CV results were 13.3% and 29.1%, respectively. For testosterone, 20 replicated samples and 14 pooled quality-control samples (two samples per batch) were included in the blood assays. The intra-assay CV and total CV were both 9.6%. Four subjects had estrone measurements below the 10 pg/ml limit of detection. To calculate a representative estrone value for measurements below this detection limit, we fitted a truncated log-normal distribution to the observed estrone data. The truncation was considered at the lower end of the distribution and the cumulative proportion at the truncation point (namely, estrone = 10 pg/ml) was used as the likelihood contribution from each of the subjects with estrone below the detection limit. The maximum likelihood estimate of the mean of the lognormal distribution was 3.079 and that of the standard deviation was 0.453. Using these maximum likelihood estimates in the lognormal distribution, we calculated the mean estrone value less than 10 pg/ml to be 8.702 pg/ml. The four estrone measurements below the limit of detection were assigned this value.
###end p 25
###begin title 26
Hormone receptor characterization
###end title 26
###begin p 27
###xml 770 772 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 773 775 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 859 861 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 862 864 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 916 918 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 919 921 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1278 1280 1277 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1342 1344 1341 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1345 1347 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 55 60 <span type="species:ncbi:9606">women</span>
###xml 216 223 <span type="species:ncbi:9606">patient</span>
Paraffin-embedded breast tumor tissue samples from 163 women were tested for this study. ER and PR proteins were assessed by immunohistochemistry in a single laboratory without knowledge of other laboratory results, patient characteristics, or outcome. Tissue blocks were selected by reviewing all histologic slides for each case. Blocks for testing were selected for the presence of representative tumor and, when available, the presence of adjacent benign epithelium (used as an internal positive control). Immunohistochemistry was performed with modified standard immunohistochemical techniques. In brief, 5 mum sections of tumor were cut onto glass slides and blocked for endogenous peroxidase. Slides were treated with microwaves in the presence of citrate buffer [43-45]. After washes, primary antibodies (monoclonal anti-PR clone 1A6 [NovoCastra Lab] [46,47] and monoclonal anti-ER clone ER1D5 [AMAC, Inc.]) [48-50] were applied to the sections and incubated for 1 hour. Slides were washed and appropriate biotinylated secondary antibody, diluted in accordance with the manufacturer's instructions (Vector Laboratories, Burlingame, CA), was applied for 30 minutes. Slides were incubated for 30 minutes with avidin-biotin complex, followed by diaminobenzidine with 8% NiCl2 for 10 minutes; nuclei were counterstained with methyl green [51,52]. Tumor cells were scored positive if nuclear immunostaining was present and more than 5% of tumor cells had positive staining.
###end p 27
###begin title 28
Genotyping
###end title 28
###begin p 29
A 50 ml fasting blood draw was collected at the time of the baseline interview. Blood was processed into serum, plasma, and buffy coat fractions and aliquots were stored at -70 to -80degreesC. DNA for genotyping was extracted from the buffy coat fraction at the Core Specimen Processing Laboratory (Fred Hutchinson Cancer Research Center) with standard techniques.
###end p 29
###begin p 30
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">213</sup>
###xml 120 127 120 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 290 291 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 799 802 767 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 1135 1142 1103 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 1145 1148 1113 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">458</sup>
###xml 1153 1160 1121 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7 </italic>
###xml 1163 1166 1131 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268</sup>
###xml 1171 1179 1139 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 1182 1184 1150 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85</sup>
###xml 1193 1200 1161 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 1204 1206 1172 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1204 1206 1172 1174 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n </italic></sub>
###xml 1256 1258 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1259 1261 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
SULT1A1 genotyping of the Arg213His polymorphism was performed with a restriction-fragment-length polymorphism assay. A SULT1A1-specific fragment containing the polymorphism was amplified in a 20 mul reaction containing 1 x GeneAmp buffer II (Applied Biosystems, Foster City, CA), 3 mM MgCl2, 200 muM deoxynucleotide triphosphates, each primer at 200 nM (forward primer 5'-AGTTGGCTCTGCAGGGTTTCT-3', reverse primer 5'-ACCACGAAGTCCACGGTCTC-3'), 100 ng of genomic DNA, and 0.5 U of AmpliTaq DNA polymerase (Applied Biosystems). Cycling was as follows: initial denaturation at 94degreesC for 5 minutes, followed by 35 cycles of 94degreesC for 30 seconds, 59degreesC for 45 seconds, and 72degreesC for 45 seconds, and final extension at 72degreesC for 5 minutes. The amplified fragment was digested with HhaI and separated on a 2% NuSieve agarose gel (Cambrex, Rockland, ME). The fragment sizes were 160 and 40 base pairs for the wild-type allele, and 200 base pairs for the variant allele. For quality control purposes, genotyping was repeated for 10% of the samples for each genotype. There were no discrepancies between the two results. UGT2B4 Asp458Glu, UGT2B7 His268Tyr, UGT2B15 Asp85Tyr, and UGT1A1 [TA]n genotyping was performed as described previously [53,54].
###end p 30
###begin title 31
Statistical methods
###end title 31
###begin p 32
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 495 504 495 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 1422 1427 <span type="species:ncbi:9606">women</span>
###xml 1527 1532 <span type="species:ncbi:9606">women</span>
###xml 2210 2215 <span type="species:ncbi:9606">women</span>
###xml 2285 2290 <span type="species:ncbi:9606">women</span>
We addressed two separate research questions, using two different statistical models. We first examined whether genotype was related to the risk of developing an ER-negative (ER-) or PR-negative (PR-) breast cancer tumor. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by using unconditional logistic regression analysis to evaluate the association between genotype and tumor receptor status. We adjusted our logistic regression analyses for variables for which we had a priori knowledge of potential contribution to breast cancer risk or to the development of hormone-dependent or hormone-independent breast tumors. Because of the small size of the study, the data were not sufficiently robust to employ specific methods to evaluate confounding. In addition to race (Caucasian/Asian), the following breast cancer risk factors were included as covariates in the analysis: age at the time of interview (continuous), age at menarche (continuous), number of ovaries remaining, number of pregnancies lasting at least 6 months (0, 1, 2, or 3 or more), menopausal status at time of baseline interview (premenopausal/postmenopausal), smoker at time of interview (yes/no), parity/age at first birth (nulliparous, age at first birth 26 or less, age at first birth more than 26), change in weight from age 18 to the age that the subject had most recently passed (35, 50, or 60 years old). Eight of the 163 women were excluded from the logistic regression analyses because of missing covariate data, leaving 155 women in the final model. Genotype indicator variables were created by using the wild-type genotype as the reference category in the regression models. Genotypes were also evaluated with dichotomous variables ('any wild-type allele' [wild-type and heterozygous individuals] versus homozygous variant individuals, and 'any variant allele' [heterozygous and homozygous variant individuals] versus wild-type individuals) when patterns suggested a dominant or recessive genotype effect, respectively. We evaluated menopausal status as a potential effect modifier but were unable to evaluate effect modification by race owing to small numbers. However, we modeled effects excluding Asian women to evaluate whether results were different when limited to Caucasian women. All logistic regression analyses were performed with SAS statistical software, version 8.2 (SAS Institute, Cary, NC).
###end p 32
###begin p 33
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 583 592 583 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 320 325 <span type="species:ncbi:9606">women</span>
###xml 1169 1174 <span type="species:ncbi:9606">women</span>
###xml 1243 1248 <span type="species:ncbi:9606">women</span>
###xml 1495 1500 <span type="species:ncbi:9606">women</span>
###xml 1580 1585 <span type="species:ncbi:9606">women</span>
###xml 1626 1631 <span type="species:ncbi:9606">women</span>
Our second research question examined whether genotype was related to sex hormone concentrations. Linear regression analysis with robust variance estimates was used to evaluate the association between UGT and SULT genotypes and circulating sex hormone concentrations (estrone, estradiol, testosterone) in postmenopausal women not taking estrogen or progesterone replacement hormones at the time of the blood draw. Hormone concentrations were natural-logarithm transformed to approximate normal distributions. We adjusted the linear regression analyses for variables for which we had a priori knowledge of potential contribution to sex hormone concentrations. Geometric mean hormone concentrations within each genotype were calculated after adjustment for age at the time of interview (continuous), percentage body fat (continuous), tamoxifen use at the time of blood draw (yes/no), alcohol use (yes/no), smoking (yes/no), number of ovaries remaining, race (Asian/Caucasian), and batch number (estrone and estradiol only). We evaluated tamoxifen use as a potential effect modifier. As with the logistic regression analyses, we evaluated whether restriction to Caucasian women altered the results. Of the 82 Caucasian and 7 Asian postmenopausal women with complete data for estrone, estradiol, height, and weight who were not taking estrogen or progesterone replacement hormones at the time of the blood draw, two were lacking body fat data and one was lacking data for plasma testosterone. These women were dropped from the multivariate linear regression analysis, resulting in 87 women with estradiol and estrone data, and 86 women with testosterone data. All linear regression analyses were performed with Stata statistical software, version 7 (Stata Corporation, College Station, TX).
###end p 33
###begin title 34
Results
###end title 34
###begin p 35
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 394 395 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 460 462 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 15 20 <span type="species:ncbi:9606">women</span>
###xml 172 177 <span type="species:ncbi:9606">women</span>
###xml 366 371 <span type="species:ncbi:9606">women</span>
A total of 163 women (150 Caucasian and 13 Asian) from Washington state were enrolled in the HEAL study and had complete baseline interview and hormone receptor data. Most women were diagnosed with Stage I breast cancer (51%) (Table 1), were postmenopausal at the time of study enrollment (60%), and had no known family history of breast cancer (51%). Most of these women had an ER-positive (ER+) or PR-positive (PR+) breast tumor and 66% had a combined ER+/PR+ tumor.
###end p 35
###begin p 36
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 107 109 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4</italic>
###xml 128 132 128 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">458 </sup>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 151 155 151 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268 </sup>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 175 178 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85 </sup>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 198 202 198 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">213 </sup>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 409 411 409 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
In Caucasians (n = 150), the observed variant allele frequencies of each gene were as follows: UGT1A1, (TA)7 = 0.31; UGT2B4, Glu458 = 0.24; UGT2B7, Tyr268 = 0.55; UGT2B15, Tyr85 = 0.56; SULT1A1, His213 = 0.38. These allele frequencies were similar to those in Caucasians in previous reports [13,34,53-56]. We did not calculate separate allele frequencies in Asians because of the small number of individuals (n = 13). In Caucasians, genotype frequencies for each gene did not deviate from Hardy-Weinberg equilibrium.
###end p 36
###begin p 37
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 134 135 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 140 141 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 156 158 156 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 194 196 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 309 317 309 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 367 375 367 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 548 555 548 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 561 569 561 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 497 502 <span type="species:ncbi:9606">women</span>
###xml 631 636 <span type="species:ncbi:9606">women</span>
As shown in Table 2, the risk of an ER- breast tumor seemed smaller for individuals with the UGT1A1 variant allele (compared with (TA)6/(TA)6: OR (TA)6/(TA)7 = 0.6, 95% CI 0.2-1.3; OR (TA)7/(TA)7 = 0.0, 95% CI 0.0-0.5; P for trend = 0.03). Further, a reduced risk of an ER- tumor might be associated with the SULT1A1 variant allele (OR = 0.6, 95% CI 0.3-1.2) and the UGT2B15 homozygous variant genotype (OR = 0.4, 95% CI 0.1-1.2). The effects were similar when the sample was limited to Caucasian women (data not shown). Trends for UGT1A1, UGT2B7, UGT2B15, and SULT1A1 were generally similar among premenopausal and postmenopausal women (data not shown).
###end p 37
###begin p 38
###xml 64 66 64 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 151 153 151 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 212 214 212 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 279 281 279 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 319 321 319 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 470 471 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 476 478 476 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 489 490 489 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 495 497 495 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 587 595 587 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 634 636 634 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 654 656 654 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 821 824 821 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85 </sup>
###xml 926 929 926 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85 </sup>
###xml 937 939 937 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1035 1043 1035 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1166 1168 1166 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1182 1183 1182 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1315 1317 1315 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1511 1518 1511 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 1521 1528 1521 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7 </italic>
###xml 27 32 <span type="species:ncbi:9606">women</span>
###xml 180 185 <span type="species:ncbi:9606">women</span>
###xml 294 299 <span type="species:ncbi:9606">women</span>
###xml 444 449 <span type="species:ncbi:9606">women</span>
###xml 572 577 <span type="species:ncbi:9606">Women</span>
###xml 716 721 <span type="species:ncbi:9606">women</span>
###xml 803 808 <span type="species:ncbi:9606">women</span>
###xml 909 914 <span type="species:ncbi:9606">women</span>
###xml 1020 1025 <span type="species:ncbi:9606">women</span>
###xml 1123 1128 <span type="species:ncbi:9606">women</span>
###xml 1271 1276 <span type="species:ncbi:9606">women</span>
Among the subpopulation of women eligible for hormone analysis (n = 89; Table 1), most (62%) were taking tamoxifen, but very few were current smokers (n = 4). Among this subgroup, women with the UGT1A1 (TA)7/(TA)7 genotype had 58% higher geometric mean estradiol concentrations (P = 0.01) than women with the (TA)6/(TA)6 wild-type genotype (Table 3) and 71% higher geometric mean estradiol concentrations (P = 0.002) than the combined group of women with either the (TA)6/(TA)6 or the (TA)6/(TA)7 genotype (9.8 pg/ml, 95% CI 8.7-11.1 versus 16.8 pg/ml, 95% CI 12.6-22.5). Women with the UGT2B15 Asp/Tyr and Tyr/Tyr genotypes had 59% (P = 0.003) and 44% (P = 0.05) higher geometric mean estradiol concentrations than women with the Asp/Asp genotype, respectively (Table 3). When genotypes were combined, women with any Tyr85 allele had 53% higher geometric mean estradiol concentrations than Asp/Asp wild-type women with no Tyr85 allele (P = 0.004; 7.2 pg/ml, 95% CI 5.6-9.4 versus 11.1 pg/ml, 95% CI 9.8-12.5). Finally, women with the SULT1A1 His/His genotype had 32% higher geometric mean testosterone concentrations than women with the wild-type Arg/Arg genotype (P = 0.03; Table 3), and 39% higher geometric mean testosterone concentrations than the combined group of women with the Arg/Arg or Arg/His genotype (P = 0.003; 26.4 ng/dl, 95% CI 24.3-28.7 versus 36.8 ng/dl, 95% CI 30.5-44.3). No statistically significant associations were observed between estradiol, estrone or testosterone concentrations and UGT2B4 or UGT2B7 genotypes. Results were similar when the analyses were restricted to Caucasians (data not shown). We did not observe that the relationship between any of the polymorphisms and circulating sex hormone concentrations differed between tamoxifen users and non-users (data not shown), but the small number of individuals within each subgroup limited our ability to observe a difference.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 91 93 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 98 100 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4</italic>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 404 412 404 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 435 437 435 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 442 444 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
This study of female breast cancer patients had two aims: first, to evaluate the risk of ER- or PR- tumors associated with polymorphisms in specific UGT and SULT genes, and second, to investigate whether plasma sex hormone concentrations varied within genotypes of these same genes. To our knowledge this is the first study to investigate the association between polymorphisms in the UGT2B4, UGT2B7, and UGT2B15 genes and risk of an ER- or PR- breast tumor.
###end p 40
###begin p 41
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 277 279 277 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 306 313 306 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 317 318 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 323 325 323 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 391 399 391 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 403 410 403 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 670 672 670 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 680 682 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8 </sub>
###xml 742 744 742 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 770 772 770 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 780 782 780 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1058 1060 1058 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1065 1067 1065 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1091 1099 1091 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 151 156 <span type="species:ncbi:9606">Women</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 595 600 <span type="species:ncbi:9606">women</span>
###xml 655 660 <span type="species:ncbi:9606">women</span>
###xml 755 760 <span type="species:ncbi:9606">women</span>
###xml 891 896 <span type="species:ncbi:9606">women</span>
###xml 1076 1081 <span type="species:ncbi:9606">women</span>
###xml 1192 1200 <span type="species:ncbi:9606">patients</span>
There is increasing evidence that hormones are important in the development of hormone-dependent and hormone-independent breast cancer tumors [37-41]. Women with ER- tumors have a worse prognosis and fewer treatment modalities are available. We observed a reduced risk of an ER- tumor in patients with the UGT1A1 (TA)7/(TA)7 genotype, and indications towards risk reduction with variants of UGT2B15 and SULT1A1. The association between breast tumor ER status and the number of TA repeats in the UGT1A1 promoter region has previously been examined in a case-control study of 200 African-American women with breast cancer [14]. In that study, premenopausal women with (TA)7 and (TA)8 'low-activity' alleles seemed to be at higher risk for an ER- tumor than women with (TA)5 and (TA)6 'high-activity' alleles (OR = 2.1, 95% CI 1.0-4.2) [14]. This elevated risk did not extend to postmenopausal women (OR = 0.8, 95% CI 0.3-1.9), which is consistent with our results among a predominantly postmenopausal population. Our finding of a somewhat reduced risk of an ER- or PR- tumor in women with the SULT1A1 Arg/His and His/His genotypes is consistent with the results of a study of 337 breast cancer patients by Nowell and colleagues [57]. Given that the hormonal milieu seems important for the development of both hormone-dependent and hormone-independent mammary tumors, our study, in conjunction with others, provides evidence that genotypes relevant to the metabolism and excretion of sex hormones might affect that milieu.
###end p 41
###begin p 42
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 142 150 142 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 265 266 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 267 269 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 331 338 328 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 350 352 347 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 506 515 503 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 538 540 535 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 548 550 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 551 553 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 712 719 709 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 729 731 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1071 1078 1068 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1 </italic>
###xml 32 37 <span type="species:ncbi:9606">women</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 603 608 <span type="species:ncbi:9606">women</span>
###xml 762 767 <span type="species:ncbi:9606">women</span>
###xml 1000 1008 <span type="species:ncbi:9606">patients</span>
###xml 1136 1141 <span type="species:ncbi:9606">women</span>
In a substudy of postmenopausal women at least 2 years after diagnosis, we observed that plasma estradiol concentrations varied by UGT1A1 and UGT2B15 genotypes. The UGT1A1 gene is involved in the glucuronidation of several sex hormones, including 17beta-estradiol [9,11]. Our finding that breast cancer patients homozygous for the UGT1A1 variant (TA)7 allele seemed to have increased concentrations of estradiol is consistent with the observation that the variant allele has lower transcriptional activity in vitro than the wild-type (TA)6 allele [12-14]. However, a study of 274 healthy postmenopausal women in the Nurses' Health Study found that neither estrone nor estradiol concentration varied depending on UGT1A1 genotype [15]. Our study was restricted to women with breast cancer, the majority of whom were on tamoxifen therapy, which alters estrogen levels, perhaps independently of these genetic factors. Our findings should therefore be confirmed in additional populations of breast cancer patients and healthy controls, to clarify the relationship between the UGT1A1 polymorphism and estradiol concentrations in both healthy women and those with breast cancer.
###end p 42
###begin p 43
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85 </sup>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 282 290 282 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 554 562 554 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 804 812 804 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 816 824 816 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 60 65 <span type="species:ncbi:9606">women</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
Our finding that concentrations of estradiol were higher in women with the UGT2B15 Tyr85 allele is surprising, given that the UGT2B15 protein is not known to glucuronidate estradiol [18,29]. Further, we did not observe that circulating testosterone concentrations varied greatly by UGT2B15 genotype, despite the fact that UGT2B15 is known to glucuronidate testosterone [18,29]. However, this might be explained by the much higher glucuronidation activity of UGT2B17 for testosterone than that of UGT2B15 [18,58]. Also surprising was the finding that the SULT1A1 His/His genotype was associated with elevated testosterone concentrations, given that SULT1A1 does not seem to conjugate testosterone [32]. It is possible that the observed associations between sex hormone concentrations and polymorphisms in UGT2B15 and SULT1A1 in breast cancer patients are valid. However, they should be viewed as possibly attributable to chance, because there are conflicting biochemical data reported in the literature.
###end p 43
###begin p 44
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4 </italic>
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7 </italic>
###xml 115 124 115 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 431 438 431 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 558 560 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 619 628 619 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
With regard to the UGT2B4 and UGT2B7 polymorphisms, there was relatively little biochemical evidence to support an a priori hypothesis about an association between these polymorphisms and circulating sex hormone concentrations or tumor receptor status. We therefore considered these analyses to be 'hypothesis generating', in which any observed association might elucidate the potential functional relevance of these polymorphisms in vivo. We did not find evidence that these polymorphisms were associated with sex hormone concentrations or the risk of an ER- or PR- breast cancer tumor. Our findings therefore support in vitro data in which these sequence variations did not seem to alter enzyme function [10,16,24,27].
###end p 44
###begin p 45
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4</italic>
###xml 411 417 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 423 431 423 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
Because genetic factors that might influence circulating sex hormone concentrations in breast cancer patients could influence response to treatment, it is important to understand these associations in breast cancer patients. The results of this study might serve as a starting point for the formation and testing of additional hypotheses regarding the potential association between polymorphisms in the UGT2B4, UGT2B7, and UGT2B15 genes and serum hormone concentrations or hormone receptor status. One strength of the study is the investigation of several genetic polymorphisms in genes relevant to sex hormone excretion or regulation and the measurement of three sex hormones.
###end p 45
###begin p 46
###xml 563 571 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1077 1081 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT </italic>
###xml 1085 1090 1085 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT </italic>
###xml 956 961 <span type="species:ncbi:9606">women</span>
###xml 1169 1174 <span type="species:ncbi:9606">women</span>
However, this study has several limitations. The small size limited the statistical power in many of the analyses and prohibited the evaluation of combined genotype effects. Additionally, the coefficients of variation for the estrone and estradiol assays were somewhat high, possibly preventing us from detecting an association. Another limitation is that we examined polymorphisms in only five genes whose protein products participate in sex hormone regulation; additional proteins involved in regulatory mechanisms that contribute to sex hormone concentrations in vivo could not be considered as part of the study. As with any genetic association study, the results must be interpreted in the light of the possibility that observed associations might be due to linkage disequilibrium between the examined polymorphism and a functional polymorphism that is the true cause of the observed difference. Finally, because this study involved mostly overweight women with breast cancer, most of whom were taking tamoxifen at the time of the study, the observed associations between UGT and SULT genotypes and circulating hormone levels might not be generalizable to healthy women.
###end p 46
###begin title 47
Conclusions
###end title 47
###begin p 48
###xml 87 89 87 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 127 135 127 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 139 146 139 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 265 272 265 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 277 285 277 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
The results of this study of female breast cancer patients indicate that the risk of ER- tumors varies by UGT1A1, and possibly UGT2B15 and SULT1A1, genotype. Further, there was some indication that plasma estradiol and testosterone concentrations varied by UGT1A1, UGT2B15, or SULT1A1 genotype. Owing to the preliminary nature of these findings, they should be validated in a larger study population.
###end p 48
###begin title 49
Competing interests
###end title 49
###begin p 50
None declared.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
CI = confidence interval; CV = coefficient of variation; ER = estrogen receptor; HEAL = Health, Eating, Activity, and Lifestyle; OR = odds ratio; PR = progesterone receptor; SEER = Surveillance, Epidemiology, and End Results; SULT = sulfotransferase; UGT = UDP-glucuronosyltransferase.
###end p 52
###begin title 53
Acknowledgements
###end title 53
###begin p 54
###xml 84 96 <span type="species:ncbi:9606">participants</span>
We thank Leslie Bernstein for thoughtful review of the manuscript, and all the HEAL participants and HEAL staff for their contributions. This study was supported by SEER contract N01 PC-67009 and by the National Cancer Institute Cancer Center Support Grant NCI 5 P30 CA15704.
###end p 54
###begin article-title 55
Serum oestradiol and breast cancer risk
###end article-title 55
###begin article-title 56
The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer
###end article-title 56
###begin article-title 57
###xml 60 65 <span type="species:ncbi:9606">women</span>
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies
###end article-title 57
###begin article-title 58
Structural and functional studies of UDP-glucuronosyltransferases
###end article-title 58
###begin article-title 59
Sulfation through the looking glass - recent advances in sulfotransferase research for the curious
###end article-title 59
###begin article-title 60
Estrogen metabolism by conjugation
###end article-title 60
###begin article-title 61
Steroid UDP glucuronosyltransferases: characterization and regulation
###end article-title 61
###begin article-title 62
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol
###end article-title 62
###begin article-title 63
###xml 65 70 <span type="species:ncbi:9606">human</span>
Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation
###end article-title 63
###begin article-title 64
###xml 51 56 <span type="species:ncbi:9606">human</span>
Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7
###end article-title 64
###begin article-title 65
###xml 78 81 <span type="species:ncbi:10116">rat</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1
###end article-title 65
###begin article-title 66
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
###end article-title 66
###begin article-title 67
Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?
###end article-title 67
###begin article-title 68
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans
###end article-title 68
###begin article-title 69
Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels
###end article-title 69
###begin article-title 70
Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene
###end article-title 70
###begin article-title 71
###xml 4 9 <span type="species:ncbi:9606">human</span>
Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives
###end article-title 71
###begin article-title 72
###xml 75 80 <span type="species:ncbi:9606">human</span>
Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members
###end article-title 72
###begin article-title 73
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance
###end article-title 73
###begin article-title 74
The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11
###end article-title 74
###begin article-title 75
###xml 26 31 <span type="species:ncbi:9606">human</span>
Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3, 4-catechol estrogens and estriol as primary substrates
###end article-title 75
###begin article-title 76
###xml 64 69 <span type="species:ncbi:9606">human</span>
Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs
###end article-title 76
###begin article-title 77
###xml 71 76 <span type="species:ncbi:9606">human</span>
Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7
###end article-title 77
###begin article-title 78
###xml 81 85 81 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268 </sup>
###xml 96 99 96 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">268</sup>
###xml 68 73 <span type="species:ncbi:9606">human</span>
The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y268 and UGT2B7H268
###end article-title 78
###begin article-title 79
Functional characterization of the UGT1A9183Gly and UGT2B7268Tyr polymorphic variants
###end article-title 79
###begin article-title 80
Expression of chimeric cDNAs in cell culture defines a region of UDP glucuronosyltransferase involved in substrate selection
###end article-title 80
###begin article-title 81
Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance
###end article-title 81
###begin article-title 82
Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene
###end article-title 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates
###end article-title 83
###begin article-title 84
###xml 29 34 <span type="species:ncbi:9606">human</span>
Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms
###end article-title 84
###begin article-title 85
###xml 46 51 <span type="species:ncbi:9606">human</span>
Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase
###end article-title 85
###begin article-title 86
###xml 31 36 <span type="species:ncbi:9606">human</span>
Steroid sulfation by expressed human cytosolic sulfotransferases
###end article-title 86
###begin article-title 87
###xml 133 138 <span type="species:ncbi:9606">women</span>
Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women
###end article-title 87
###begin article-title 88
###xml 44 50 <span type="species:ncbi:9606">humans</span>
Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype
###end article-title 88
###begin article-title 89
Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol
###end article-title 89
###begin article-title 90
Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk
###end article-title 90
###begin article-title 91
###xml 39 43 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 45 49 <span type="species:ncbi:10116">rats</span>
###xml 55 61 <span type="species:ncbi:9606">humans</span>
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis
###end article-title 91
###begin article-title 92
Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features
###end article-title 92
###begin article-title 93
###xml 114 119 <span type="species:ncbi:9606">women</span>
Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women
###end article-title 93
###begin article-title 94
Risk factors for breast cancer according to estrogen and progesterone receptor status
###end article-title 94
###begin article-title 95
The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer
###end article-title 95
###begin article-title 96
Adiposity and sex hormones in postmenopausal breast cancer survivors
###end article-title 96
###begin article-title 97
Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques
###end article-title 97
###begin article-title 98
Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1
###end article-title 98
###begin article-title 99
Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues
###end article-title 99
###begin article-title 100
Immunohistochemical evaluation of estrogen and progesterone receptors in paraffin-embedded, formalin-fixed endometrial tissues: comparison with enzyme immunoassay and immunohistochemical analysis of frozen tissue
###end article-title 100
###begin article-title 101
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases
###end article-title 101
###begin article-title 102
Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer
###end article-title 102
###begin article-title 103
###xml 81 86 <span type="species:ncbi:9606">human</span>
Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies
###end article-title 103
###begin article-title 104
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer
###end article-title 104
###begin article-title 105
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures
###end article-title 105
###begin article-title 106
Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry
###end article-title 106
###begin article-title 107
UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations
###end article-title 107
###begin article-title 108
###xml 35 40 <span type="species:ncbi:9606">human</span>
Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)
###end article-title 108
###begin article-title 109
Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects
###end article-title 109
###begin article-title 110
Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations
###end article-title 110
###begin article-title 111
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
###end article-title 111
###begin article-title 112
###xml 58 63 <span type="species:ncbi:9606">human</span>
Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids
###end article-title 112
###begin title 113
Figures and Tables
###end title 113
###begin p 114
###xml 52 57 <span type="species:ncbi:9606">women</span>
Selected characteristics of the Caucasian and Asian women enrolled in the Health, Eating, Activity, and Lifestyle study and asubpopulation used for investigating associations with circulating sex hormones at the 24-month follow-up
###end p 114
###begin p 115
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 101 106 <span type="species:ncbi:9606">women</span>
ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor. aRestricted to postmenopausal women not taking estrogen or progesterone therapy at the time of blood draw for investigation of associations between genotype and sex hormone concentrations. bMean (SD).
###end p 115
###begin p 116
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT1A1</italic>
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B4</italic>
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B7</italic>
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBT2B15</italic>
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
UGT1A1, UGT2B4, UGT2B7, UBT2B15, and SULT1A1 genotypes and risk of ER- and PR- breast tumors in Caucasian and Asian female breast cancer patients, Washington state
###end p 116
###begin p 117
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 393 394 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 669 671 669 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 764 765 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor. aAdjusted for age, menopausal status, age at menarche, number of pregnancies lasting at least 6 months (0, 1, 2, or 3 or more), parity/age at first birth (nulliparous, age at first birth 26 or less, age at first birth more than 26), weight change since age 18, race (Asian/Caucasian), smoking, and number of ovaries remaining. bGenotypes were also evaluated with the use of dichotomous variables ('any wild-type allele' [wild-type and heterozygous individuals] and 'any variant allele' [heterozygous and homozygous variant individuals]) when patterns suggested a dominant or recessive genotype effect. cP for trend = 0.03. dOR for combined group of heterozygous and homozygous variant individuals. eOR for combined group of wild type and heterozygous individuals.
###end p 117
###begin p 118
###xml 144 149 <span type="species:ncbi:9606">women</span>
Geometric mean estradiol (pg/ml), estrone (pg/ml), and testosterone (ng/dl) concentrations by genotype among postmenopausal Caucasian and Asian women with breast cancer in Washington state
###end p 118
###begin p 119
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
CI, confidence interval; het, heterozygous; var, homozygous variant; wt, wild-type. aGeometric mean estimates are for an individual with mean values of all covariates; adjusted for age, use of tamoxifen at the time of blood draw, smoking, alcohol use, percentage body fat, batch (estrone and estradiol only), number of ovaries remaining, and race (Asian/Caucasian).
###end p 119

